Adverse events940

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

241 to 260 of 940

Type	Event	Organ system	Group	Affected	At risk	Events
other	Injection site haematoma	General disorders	Group A: Placebo SC QW (DBTP)	2	39	2
other	Injection site haematoma	General disorders	Group A: Evinacumab 300 mg SC Q2W (DBTP)	0	39	0
other	Injection site haematoma	General disorders	Group A: Evinacumab 300 mg SC QW (DBTP)	3	42	5
other	Injection site haematoma	General disorders	Group A: Evinacumab 450 mg SC QW (DBTP)	0	40	0
other	Injection site haematoma	General disorders	Group B: Placebo IV Q4W (DBTP)	0	33	0
other	Injection site haematoma	General disorders	Group B: Evinacumab 5 mg/kg IV Q4W (DBTP)	0	36	0
other	Injection site haematoma	General disorders	Group B: Evinacumab 15 mg/kg IV Q4W (DBTP)	0	37	0
other	Injection site haematoma	General disorders	Group B: Placebo IV Q4W (OLTP)	0	31	0
other	Injection site haematoma	General disorders	Group B: Evinacumab 5 mg/kg IV Q4W (OLTP)	0	32	0
other	Injection site haematoma	General disorders	Group B: Evinacumab 15 mg/kg IV Q4W (OLTP)	0	33	0
other	Injection site haemorrhage	General disorders	Group A: Placebo SC QW (DBTP)	1	39	1
other	Injection site haemorrhage	General disorders	Group A: Evinacumab 300 mg SC Q2W (DBTP)	1	39	6
other	Injection site haemorrhage	General disorders	Group A: Evinacumab 300 mg SC QW (DBTP)	3	42	3
other	Injection site haemorrhage	General disorders	Group A: Evinacumab 450 mg SC QW (DBTP)	0	40	0
other	Injection site haemorrhage	General disorders	Group B: Placebo IV Q4W (DBTP)	0	33	0
other	Injection site haemorrhage	General disorders	Group B: Evinacumab 5 mg/kg IV Q4W (DBTP)	0	36	0
other	Injection site haemorrhage	General disorders	Group B: Evinacumab 15 mg/kg IV Q4W (DBTP)	0	37	0
other	Injection site haemorrhage	General disorders	Group B: Placebo IV Q4W (OLTP)	0	31	0
other	Injection site haemorrhage	General disorders	Group B: Evinacumab 5 mg/kg IV Q4W (OLTP)	0	32	0
other	Injection site haemorrhage	General disorders	Group B: Evinacumab 15 mg/kg IV Q4W (OLTP)	0	33	0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Previous page Next page

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03175367/events?page=13

API reference For AI assistants